News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fibrocell Science, Inc. Receives Orphan Drug Designation For Genetically-Modified Autologous Human Fibroblasts To Advance Treatment Development for Recessive Dystrophic Epidermolysis Bullosa (RDEB)


6/13/2014 7:53:39 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its genetically-modified autologous human fibroblasts to treat dystrophic epidermolysis bullosa (DEB), a broad category of rare and severe genetic skin diseases that includes RDEB. Fibrocell is working with leading medical centers—whose research focuses on all forms of epidermolysis bullosa, including DEB and RDEB—to advance development of its lead therapeutic candidate for the most severe form of epidermolysis bullosa, RDEB.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES